Management of diabetic nephropathy: the role of sirtuin-1

Future Med Chem. 2019 Sep;11(17):2241-2245. doi: 10.4155/fmc-2019-0153.

Authors

Wanning Wang^{1

2}, Weixia Sun¹, Yanli Cheng¹, Zhonggao Xu¹, Lu Cai^{2

3}

Affiliations

¹ Department of Nephrology, the First Hospital of Jilin University, Changchun 130021, China.
² Pediatric Research Institute, Department of Pediatrics, the University of Louisville School of Medicine, Louisville, KY 40292, USA.
³ Departments of Radiation Oncology, Pharmacology & Toxicology, the University of Louisville School of Medicine, Louisville, KY 40292, USA.

PMID: 31581918
DOI: 10.4155/fmc-2019-0153

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

AMP-Activated Protein Kinase Kinases
Animals
Diabetes Mellitus / drug therapy
Diabetes Mellitus / metabolism*
Diabetic Nephropathies / drug therapy
Diabetic Nephropathies / metabolism*
Down-Regulation / drug effects
Homeostasis / drug effects
Humans
Hypoglycemic Agents / pharmacology
Insulin / pharmacology
Insulin Resistance
Protein Kinases / metabolism
Signal Transduction
Sirtuin 1 / metabolism*

Substances

Hypoglycemic Agents
Insulin
Protein Kinases
AMP-Activated Protein Kinase Kinases
Sirtuin 1